Abstract:
The invention relates to mutant nucleic acids and proteins from the metabolic pathway of fine chemicals, methods for the production of genetically modified production organisms, methods for the production of fine chemicals by cultivating said genetically modified organisms, and said genetically modified organisms.
Abstract:
The invention relates to the use of cyclic compounds as ligands of integrin receptors, in particular as ligands of the alpha vss3 integrin receptor. The invention also relates to the novel compounds, to the use thereof and to pharmaceutical preparations which contain said compounds. Examples of said compounds include benzazepines, benzodiazepines and thieno[3,2-b]azepines, used for treating arteriosclerosis, rheumatoid arthritis, restenosis after vessel damage or stent implantation, angioplasty, acute kidney failure, microangiopathy associated with angiogenesis, diabetic angiopathy, thrombocyte-mediated vascular occlusion, arterial thrombosis, congestive heart-failure, myocardial infarct, apoplexy, cancer, osteoporosis, hypertension, psoriasis or viral, parasitic or bacterial diseases, inflammation, wound healing, hyperparathyroidism, Paget's bone disease, malignant hypercalcemia, or metastatic osteolytic lesions.
Abstract:
The invention relates to novel compounds that bind to integrin receptor ligands. The invention also relates to the production thereof, to their use as integrin receptor ligands and to their use for treating diseases, to pharmaceutical preparations that contain said compounds and to pharmaceutical preparations that contain at least one additional active compound.
Abstract:
The invention relates to novel compounds which bind to integrin receptors, in particular as ligands for the alpha V beta 3 integrin receptor, the use thereof and pharmaceutical preparations containing said compounds.
Abstract:
The invention relates to novel compounds of formula (I) which bind to integrin receptors, wherein G and L have the following meaning: L is a structural element of formula IL, wherein T represents a COOH group or a radical that can be hydrolyzed to obtain COOH and U- represents (XL)a-(CRL RL )b-, -CRL =CRL -, ethylene or =CRL -, wherein a is 0 or 1; b is 0, 1 or 2; XL represents CRL RL , NRL , oxygen or sulfur and G is a structural element of formula IG, wherein the insertion of structural element G can occur in both orientations and XO represents nitrogen or CRG . The invention also relates to the production of said compounds and to their use as medicaments.
Abstract:
The invention relates to novel compounds of formula (I) which bind to integrin receptors, wherein G and L have the following meaning: L is a structural element of formula IL, wherein T represents a COOH group or a radical that can be hydrolyzed to obtain COOH and U- represents (XL)a-(CRL RL )b-, -CRL =CRL -, ethylene or =CRL -, wherein a is 0 or 1; b is 0, 1 or 2; XL represents CRL RL , NRL , oxygen or sulfur and G is a structural element of formula IG, wherein the insertion of structural element G can occur in both orientations and XO represents nitrogen or CRG . The invention also relates to the production of said compounds and to their use as medicaments.
Abstract:
The invention relates to mutant nucleic acids and proteins from the metaboli c pathway of fine chemicals, methods for the production of genetically modifie d production organisms, methods for the production of fine chemicals by cultivating said genetically modified organisms, and said genetically modifi ed organisms.
Abstract:
The invention relates to novel compounds which bind to integrin receptors, to their preparation, to their use as integrin receptor ligands and for treating diseases, to pharmaceutical preparations comprising these compounds, and to pharmaceutical preparations comprising at least one other active compound.
Abstract:
The invention relates to novel compounds which bind to integrin receptors, their use as ligands of integrin receptors, in particular as ligands of the αv&bgr;3 integrin receptor, and pharmaceutical preparations comprising these compounds.